Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.57
NKTR's Cash-to-Debt is ranked lower than
75% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NKTR: 1.57 )
Ranked among companies with meaningful Cash-to-Debt only.
NKTR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.73  Med: 1.57 Max: 46.5
Current: 1.57
0.73
46.5
Equity-to-Asset 0.16
NKTR's Equity-to-Asset is ranked lower than
88% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NKTR: 0.16 )
Ranked among companies with meaningful Equity-to-Asset only.
NKTR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.34 Max: 0.9
Current: 0.16
-0.21
0.9
Piotroski F-Score: 3
Altman Z-Score: -0.07
Beneish M-Score: -3.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -68.22
NKTR's Operating Margin % is ranked higher than
53% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NKTR: -68.22 )
Ranked among companies with meaningful Operating Margin % only.
NKTR' s Operating Margin % Range Over the Past 10 Years
Min: -173.91  Med: -74.45 Max: -8.21
Current: -68.22
-173.91
-8.21
Net Margin % -92.80
NKTR's Net Margin % is ranked lower than
51% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NKTR: -92.80 )
Ranked among companies with meaningful Net Margin % only.
NKTR' s Net Margin % Range Over the Past 10 Years
Min: -211.67  Med: -65.44 Max: -12
Current: -92.8
-211.67
-12
ROA % -31.36
NKTR's ROA % is ranked lower than
51% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NKTR: -31.36 )
Ranked among companies with meaningful ROA % only.
NKTR' s ROA % Range Over the Past 10 Years
Min: -34.75  Med: -17.66 Max: -4.39
Current: -31.36
-34.75
-4.39
ROC (Joel Greenblatt) % -162.40
NKTR's ROC (Joel Greenblatt) % is ranked higher than
59% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NKTR: -162.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NKTR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -182.91  Med: -89.14 Max: -9.76
Current: -162.4
-182.91
-9.76
3-Year Revenue Growth Rate -2.70
NKTR's 3-Year Revenue Growth Rate is ranked lower than
61% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NKTR: -2.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NKTR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -31.6  Med: 10.3 Max: 62.2
Current: -2.7
-31.6
62.2
3-Year EBITDA Growth Rate -9.00
NKTR's 3-Year EBITDA Growth Rate is ranked lower than
60% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NKTR: -9.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NKTR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.5  Med: 7.2 Max: 109.1
Current: -9
-71.5
109.1
3-Year EPS without NRI Growth Rate -7.70
NKTR's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NKTR: -7.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NKTR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: 3.55 Max: 100.4
Current: -7.7
-44.4
100.4
GuruFocus has detected 3 Warning Signs with Nektar Therapeutics Inc $NKTR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NKTR's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NKTR Guru Trades in Q1 2016

Paul Tudor Jones 13,700 sh (New)
PRIMECAP Management 20,010,086 sh (+1.14%)
Steven Cohen 9,200 sh (-47.43%)
» More
Q2 2016

NKTR Guru Trades in Q2 2016

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 20,002,586 sh (-0.04%)
» More
Q3 2016

NKTR Guru Trades in Q3 2016

Stanley Druckenmiller 572,100 sh (New)
PRIMECAP Management 20,006,621 sh (+0.02%)
» More
Q4 2016

NKTR Guru Trades in Q4 2016

PRIMECAP Management 21,436,186 sh (+7.15%)
Stanley Druckenmiller Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NKTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RARE, NAS:CLVS, NAS:ICPT, OTCPK:BTGGF, NAS:CBPO, NAS:SAGE, NAS:AGIO, NYSE:XON, NAS:JUNO, NAS:PTLA, NAS:LGND, NAS:AVXS, NAS:PRTA, OTCPK:ABCZF, NAS:TBPH, NAS:BLUE, NAS:NBIX, NYSE:CBM, NAS:TECH, OTCPK:VNAPF » details
Traded in other countries:ITH.Germany,
Headquarter Location:USA
Nektar Therapeutics Inc is a research-based biopharmaceutical company. The company develops a pipeline of drug candidates that utilizes its PEGylation and polymer conjugate technology platforms that are designed to develop molecular entities.

Nektar Therapeutics Inc is a biopharmaceutical company that seeks to enable the development of new molecules to treat a number of therapeutic areas including oncology, pain, anti-infectives, and immunology. The company's research and development activities involve small-molecule drugs, peptides, and protein biologic drug candidates. The company decides on a candidate-by-candidate basis how far to advance clinical development and whether to commercialize products on its own, seek a partner, or pursue a combination of these approaches. Nektar's partnershipaims to fund continued clinical development, manage the regulatory filing process, and market and sell drugs in various geographies.

Ratios

vs
industry
vs
history
PB Ratio 33.62
NKTR's PB Ratio is ranked lower than
97% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. NKTR: 33.62 )
Ranked among companies with meaningful PB Ratio only.
NKTR' s PB Ratio Range Over the Past 10 Years
Min: 1.97  Med: 5.91 Max: 355.63
Current: 33.62
1.97
355.63
PS Ratio 16.02
NKTR's PS Ratio is ranked lower than
61% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. NKTR: 16.02 )
Ranked among companies with meaningful PS Ratio only.
NKTR' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 8.81 Max: 19.44
Current: 16.02
1.76
19.44
EV-to-EBIT -33.13
NKTR's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. NKTR: -33.13 )
Ranked among companies with meaningful EV-to-EBIT only.
NKTR' s EV-to-EBIT Range Over the Past 10 Years
Min: -147.1  Med: -11.6 Max: 36.7
Current: -33.13
-147.1
36.7
EV-to-EBITDA -38.47
NKTR's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. NKTR: -38.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
NKTR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1854.2  Med: -11.5 Max: 243.9
Current: -38.47
-1854.2
243.9
Current Ratio 5.90
NKTR's Current Ratio is ranked higher than
62% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. NKTR: 5.90 )
Ranked among companies with meaningful Current Ratio only.
NKTR' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 5.9 Max: 16.32
Current: 5.9
1
16.32
Quick Ratio 5.75
NKTR's Quick Ratio is ranked higher than
62% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. NKTR: 5.75 )
Ranked among companies with meaningful Quick Ratio only.
NKTR' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.8 Max: 16.32
Current: 5.75
0.96
16.32
Days Inventory 132.21
NKTR's Days Inventory is ranked lower than
51% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. NKTR: 132.21 )
Ranked among companies with meaningful Days Inventory only.
NKTR' s Days Inventory Range Over the Past 10 Years
Min: 33.21  Med: 132.83 Max: 185.48
Current: 132.21
33.21
185.48
Days Sales Outstanding 34.59
NKTR's Days Sales Outstanding is ranked higher than
76% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. NKTR: 34.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
NKTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.46  Med: 27.52 Max: 57.61
Current: 34.59
5.46
57.61
Days Payable 34.02
NKTR's Days Payable is ranked lower than
69% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. NKTR: 34.02 )
Ranked among companies with meaningful Days Payable only.
NKTR' s Days Payable Range Over the Past 10 Years
Min: 8.88  Med: 35.37 Max: 144.1
Current: 34.02
8.88
144.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.60
NKTR's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. NKTR: -9.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NKTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -36.1  Med: -8.5 Max: -0.7
Current: -9.6
-36.1
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 241.75
NKTR's Price-to-Tangible-Book is ranked lower than
99% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. NKTR: 241.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NKTR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.71  Med: 6.15 Max: 241.75
Current: 241.75
3.71
241.75
Price-to-Median-PS-Value 1.82
NKTR's Price-to-Median-PS-Value is ranked lower than
83% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NKTR: 1.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NKTR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1.19 Max: 4.57
Current: 1.82
0.26
4.57
Earnings Yield (Greenblatt) % -2.99
NKTR's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. NKTR: -2.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NKTR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.17  Med: 3.6 Max: 4.9
Current: -2.99
-3.17
4.9

More Statistics

Revenue (TTM) (Mil) $165.4
EPS (TTM) $ -1.10
Beta2.33
Short Percentage of Float14.05%
52-Week Range $11.41 - 24.88
Shares Outstanding (Mil)153.83

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 180 199 220
EPS ($) -0.97 -0.90 -0.64
EPS without NRI ($) -0.97 -0.90 -0.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NKTR

Headlines

Articles On GuruFocus.com
Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting Apr 20 2017 
Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American A Apr 04 2017 
4 Biotech Stocks to Watch Mar 22 2017 
Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics Feb 15 2016 
Weekly CEO Sells Highlight: Cadence Design Systems Inc., Nektar Therapeutics Inc., Netflix Inc., Pho Sep 27 2015 
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting Apr 20 2017
How Nektar Therapeutics' Latest Drug Could Shake Up the Market for Pain Medicine Apr 19 2017
Can Drugmakers Cure the Opioid Crisis? Apr 18 2017
Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology Apr 10 2017
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar... Apr 07 2017
Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue? Apr 07 2017
3 of the Best & Worst Performing Drug Stocks of Q1 Apr 06 2017
Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American... Apr 04 2017
Cramer's lightning round: If we get two rate hikes, this stock's a good buy Apr 03 2017
3 Revolutionary Drugs for Chronic Pain Mar 30 2017
Western Digital, Nektar Therapeutics And Two More Stocks Breaking Out Mar 30 2017
Harry Boxer’s five technology and biotechnology stocks to watch Mar 29 2017
Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell... Mar 27 2017
Trump is tapping Chris Christie to tackle the opioid epidemic — here's a fix scientists hope he'll... Mar 27 2017
Could Nektar Therapeutics Be Worth More? Mar 23 2017
Nektar Therapeutics (NKTR): Here’s What Just Happened Mar 21 2017
Nektar's Pain Drug Positive in Phase III Study; Shares Gain Mar 21 2017
Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Mar 21 2017
After-hours buzz: ESPR, NKTR, MMSI & more Mar 20 2017
Biotech Hits 11-Year High On Potential To Dethrone Oxycodone Mar 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)